Avalo Therapeutics Inc
AVTX
Market Cap$9.92M
Close$
$-0.02
100.2% downside
Current Fair Value
100.2% downsideOvervalued by 100.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.92 Million |
|---|---|
| Enterprise Value | $-100,259,693.00 |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-0.51 |
| Beta | 0.0 |
| Outstanding Shares | 1,034,130 |
| Avg 30 Day Volume | 66,390 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.07 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 9.64 |
| Price to Book Ratio | -0.1 |
| Enterprise Value to Revenue | -69.19 |
| Enterprise Value to EBIT | 5.04 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Avalo Therapeutics Inc
31 employeesCerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that ad...